Aliases & Classifications for Paraplegia

MalaCards integrated aliases for Paraplegia:

Name: Paraplegia 12 74 52 43 15 17 71
Severe or Complete Loss of Motor Function in the Lower Extremities and Lower Portions of the Trunk 52
Paraplegia, Lower 12

Classifications:



External Ids:

Disease Ontology 12 DOID:607
ICD9CM 34 344.1
MeSH 43 D010264
NCIt 49 C50687
SNOMED-CT 67 60389000
ICD10 32 G82.2 G82.20
UMLS 71 C0030486

Summaries for Paraplegia

MalaCards based summary : Paraplegia, also known as severe or complete loss of motor function in the lower extremities and lower portions of the trunk, is related to spastic paraplegia 11, autosomal recessive and spastic paraplegia 77, autosomal recessive, and has symptoms including ophthalmoplegia, hemiplegia and paraparesis. An important gene associated with Paraplegia is SPAST (Spastin), and among its related pathways/superpathways is Endocytosis. The drugs Acetazolamide and Succinylcholine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, bone and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Paraplegia is an impairment in motor or sensory function of the lower extremities. The word comes from... more...

Related Diseases for Paraplegia

Diseases related to Paraplegia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1144)
# Related Disease Score Top Affiliating Genes
1 spastic paraplegia 11, autosomal recessive 34.8 ZFYVE26 SPG7 SPG21 SPG11
2 spastic paraplegia 77, autosomal recessive 34.7 ZFYVE26 SPG11 CYP7B1
3 spastic paraplegia 49, autosomal recessive 34.7 ZFYVE26 SPG21 SPG11 DDHD1
4 spastic paraplegia 64, autosomal recessive 34.7 SPG7 SPG21 SPG11
5 spastic paraplegia 5a, autosomal recessive 34.7 ZFYVE26 SPG7 SPG11 SPAST KIF5A CYP7B1
6 spastic paraplegia 56, autosomal recessive 34.7 SPG21 SPG11 DDHD1
7 spastic paraplegia 53, autosomal recessive 34.7 SLC33A1 RTN2 ATL1
8 spastic paraplegia 28, autosomal recessive 34.6 SPG7 SPG11 REEP1 DDHD1 CYP7B1
9 spastic paraplegia 35, autosomal recessive 34.6 ZFYVE26 WASHC5 SPG7 SPG21 SPG11 REEP1
10 spastic paraplegia 20, autosomal recessive 34.6 ZFYVE26 SPG7 SPG21 SPG11 SPAST SPART
11 spastic paraplegia 54, autosomal recessive 34.6 SPG7 SPG21 SPG11 REEP1 DDHD1
12 spastic paraplegia 55, autosomal recessive 34.6 ZFYVE26 SPG21 SPG11 DDHD1
13 spastic paraplegia 63, autosomal recessive 34.6 SPG21 SPG11
14 spastic paraplegia 46, autosomal recessive 34.6 ZFYVE26 SPG7 SPG21 SPG11 DDHD1
15 spastic paraplegia 57, autosomal recessive 34.6 SPG11 REEP1 KIF5A KIF1A ERLIN2
16 spastic paraplegia 61, autosomal recessive 34.6 SPG21 SPAST RTN2 REEP1 ATL1
17 spastic paraplegia 41, autosomal dominant 34.6 SPG21 SPAST
18 spastic paraplegia 25, autosomal recessive 34.5 ZFYVE26 WASHC5 SPG21 SLC33A1
19 spastic paraplegia 24, autosomal recessive 34.5 SPG7 SPG21 CYP7B1
20 spastic paraplegia 34, x-linked 34.5 ZFYVE26 WASHC5 SPG21 SLC33A1
21 spastic paraplegia 16, x-linked 34.5 ZFYVE26 WASHC5 SPG21 SPG11 SPAST SLC33A1
22 spastic paraplegia 37, autosomal dominant 34.5 ZFYVE26 WASHC5 SPG21 SLC33A1
23 spastic paraplegia 19, autosomal dominant 34.5 ZFYVE26 WASHC5 SPG21 SLC33A1
24 spastic paraplegia 29, autosomal dominant 34.5 ZFYVE26 WASHC5 SPG21 SLC33A1
25 spastic paraplegia 32, autosomal recessive 34.5 ZFYVE26 SPG7 SPG21 SPG11 SLC33A1
26 spastic paraplegia 27, autosomal recessive 34.5 SPG21 SLC33A1
27 spastic paraplegia 52, autosomal recessive 34.5 ZFYVE26 SPG21 SPG11 RTN2
28 spastic paraplegia 3, autosomal dominant 34.5 ZFYVE26 WASHC5 SPG11 SPAST RTN2 REEP1
29 spastic paraplegia 14, autosomal recessive 34.4 ZFYVE26 WASHC5 SPG21 SPG11 SPAST SLC33A1
30 spastic paraplegia 43, autosomal recessive 34.4 ZFYVE27 ZFYVE26 SPG11 SPAST SLC33A1 ERLIN2
31 spastic paraplegia 30, autosomal recessive 34.4 WASHC5 SPG21 SPG11 SPAST REEP1 NIPA1
32 hereditary spastic paraplegia 51 34.3 ZFYVE26 SPG11 RTN2 NIPA1
33 spastic paraplegia 44, autosomal recessive 34.3 ZFYVE27 ZFYVE26 WASHC5 SPG21 SLC33A1 PLP1
34 spastic paraplegia 17, autosomal dominant 34.3 ZFYVE26 WASHC5 SPG21 SPG11 SPAST SPART
35 spastic paraplegia 26, autosomal recessive 34.3 ZFYVE26 WASHC5 SPG21 SPG11 SPAST SPART
36 spastic paraplegia 50, autosomal recessive 34.3 ZFYVE26 WASHC5 SPG11 RTN2 NIPA1 ERLIN2
37 spastic paraplegia 47, autosomal recessive 34.3 ZFYVE26 WASHC5 SPG21 SPG11 REEP1 ERLIN2
38 complex hereditary spastic paraplegia 34.3 SPG7 SPG11 NIPA1 CYP7B1
39 spastic paraplegia 48, autosomal recessive 34.2 ZFYVE26 WASHC5 SPG21 SPG11 SPAST RTN2
40 hereditary spastic paraplegia 72 34.2 ZFYVE26 SPG21 SPG11 SPAST RTN2 REEP1
41 hereditary spastic paraplegia 23 34.2 ZFYVE26 WASHC5 SPG21 SPG11 SPART SLC33A1
42 spastic paraplegia 31, autosomal dominant 34.1 ZFYVE27 ZFYVE26 WASHC5 SPG7 SPG21 SPG11
43 spastic paraplegia 18, autosomal recessive 34.1 ZFYVE26 WASHC5 SPG7 SPG21 SPG11 REEP1
44 spastic paraplegia 12, autosomal dominant 34.0 ZFYVE27 ZFYVE26 WASHC5 SPG21 SPG11 SPAST
45 mast syndrome 34.0 ZFYVE27 SPG21 SPG11 SPART
46 spastic paraplegia 2, x-linked 34.0 ZFYVE27 ZFYVE26 WASHC5 SPG7 SPG21 SPG11
47 spastic paraplegia 39, autosomal recessive 34.0 ZFYVE26 WASHC5 SPG21 SPG11 SPAST SPART
48 spastic paraplegia 76, autosomal recessive 34.0 SPG7 CYP7B1
49 pure hereditary spastic paraplegia 33.9 SPAST RTN2 PLP1 NIPA1 KIF5A ERLIN2
50 spastic paraplegia 33, autosomal dominant 33.9 ZFYVE27 WASHC5 SPG21 SPAST SPART SLC33A1

Comorbidity relations with Paraplegia via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Multiple Sclerosis
Neurogenic Bladder Osteoporosis
Paralytic Ileus Prostate Cancer
Protein-Energy Malnutrition Spinal Cord Disease
Vascular Myelopathy

Graphical network of the top 20 diseases related to Paraplegia:



Diseases related to Paraplegia

Symptoms & Phenotypes for Paraplegia

UMLS symptoms related to Paraplegia:


ophthalmoplegia, hemiplegia, paraparesis, paraplegia, ataxic, monoparesis, paraplegia, cerebral, paraplegia, spinal, monoplegia of lower limb affecting unspecified side, paraplegia, flaccid

GenomeRNAi Phenotypes related to Paraplegia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.98 RTN2
2 Decreased viability GR00402-S-2 9.98 ATL1 CYP7B1 DDHD1 ERLIN2 HSPD1 KIF1A
3 no effect GR00402-S-1 9.62 ATL1 CYP7B1 DDHD1 ERLIN2 HSPD1 KIF1A

MGI Mouse Phenotypes related to Paraplegia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.73 ATL1 HSPD1 KIF1A KIF5A PLP1 REEP1
2 nervous system MP:0003631 9.36 HSPD1 KIF1A KIF5A PLP1 REEP1 SLC33A1

Drugs & Therapeutics for Paraplegia

Drugs for Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Succinylcholine Approved Phase 4 306-40-1 5314
3 Natriuretic Agents Phase 4
4 Anticonvulsants Phase 4
5 Carbonic Anhydrase Inhibitors Phase 4
6 diuretics Phase 4
7 Neuromuscular Agents Phase 4
8 Neuromuscular Blocking Agents Phase 4
9
Minocycline Approved, Investigational Phase 2, Phase 3 10118-90-8 5281021
10
Acetylcholine Approved, Investigational Phase 2, Phase 3 51-84-3 187
11
Fenofibrate Approved Phase 2, Phase 3 49562-28-9 3339
12
4-Aminopyridine Approved Phase 3 504-24-5 1727
13 Cortivazol Investigational Phase 3 1110-40-3
14 Anti-Bacterial Agents Phase 2, Phase 3
15 Anti-Infective Agents Phase 2, Phase 3
16 Hypolipidemic Agents Phase 2, Phase 3
17 Lipid Regulating Agents Phase 2, Phase 3
18 Antimetabolites Phase 2, Phase 3
19 Neurotransmitter Agents Phase 2, Phase 3
20 Acetylcholine Release Inhibitors Phase 2, Phase 3
21 Botulinum Toxins Phase 2, Phase 3
22 Cholinergic Agents Phase 2, Phase 3
23 Potassium Channel Blockers Phase 3
24
Atorvastatin Approved Phase 2 134523-00-5 60823
25
Resveratrol Approved, Experimental, Investigational Phase 2 501-36-0 445154
26
chenodeoxycholic acid Approved Phase 2 474-25-9 10133
27
Dopamine Approved Phase 1, Phase 2 51-61-6, 62-31-7 681
28
Levodopa Approved Phase 1, Phase 2 59-92-7 6047
29
Buspirone Approved, Investigational Phase 1, Phase 2 36505-84-7 2477
30
Carbidopa Approved Phase 1, Phase 2 28860-95-9 34359
31
Evolocumab Approved Phase 1, Phase 2 1256937-27-5
32 Protamines Phase 2
33 Cathartics Phase 2
34 Anti-Inflammatory Agents, Non-Steroidal Phase 2
35 Antioxidants Phase 2
36 Platelet Aggregation Inhibitors Phase 2
37 Analgesics, Non-Narcotic Phase 2
38 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
39 Laxatives Phase 2
40 Antirheumatic Agents Phase 2
41 Protective Agents Phase 2
42 abobotulinumtoxinA Phase 2
43 incobotulinumtoxinA Phase 2
44 Hemagglutinins Phase 2
45 Pharmaceutical Solutions Phase 2
46 Botulinum Toxins, Type A Phase 2
47 Anti-Anxiety Agents Phase 1, Phase 2
48 Dopamine Agents Phase 1, Phase 2
49 Tranquilizing Agents Phase 1, Phase 2
50 Psychotropic Drugs Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair Unknown status NCT01889498 Phase 4 Acetazolamide
2 The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
3 Characterizing Fade Upon Train-of Four Stimulation During Onset and Offset of Neuromuscular Block Produced by Succinlycholine Completed NCT02425449 Phase 4 Succinylcholine
4 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
5 Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica - Controlled Randomized Trial With Double Blind Evaluation Unknown status NCT02151045 Phase 3
6 Activity-Dependent Plasticity After Spinal Cord Injury Unknown status NCT00059553 Phase 2, Phase 3
7 Botulinum Toxin in Patients With Hereditary Spastic Paraplegia: a Randomized, Double-blind, Placebo-controlled, Crossover Study Completed NCT02604186 Phase 2, Phase 3
8 Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network Completed NCT00614744 Phase 2, Phase 3
9 An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI Completed NCT02455336 Phase 2, Phase 3 Fenofibrate
10 Quality of Life, Efficacy and Safety of High Doses of 4-aminopyridine in Patients With Clinically Complete Chronic Spinal Cord Injury: Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial Not yet recruiting NCT03899584 Phase 3 4-Aminopyridine;Placebo oral capsule
11 A Multi-center, Double-blind, Randomized, Placebo-controlled, Delayedstart Phase II/III Study to Assess the Efficacy and Safety of Neuro-Cells in (Sub)Acute Spinal Cord Injury Patients Not yet recruiting NCT03935724 Phase 2, Phase 3
12 Optimizing Cooling Strategies at < 6 Hours of Age for Neonatal Hypoxic-Ischemic Encephalopathy Terminated NCT01192776 Phase 3
13 A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Cethrin in Subjects With Acute Cervical Spinal Cord Injury Withdrawn NCT02053883 Phase 2, Phase 3 Cethrin (BA-210);Placebo
14 Randomised Open Study of the Efficiency and Tolerance of the Use of a Corset on the Respiratory Function of Spinal Cord Injury Patients Withdrawn NCT01569360 Phase 3
15 Safety and Efficacy of Autologous Neural Stem Cell Transplantation in Patients With Traumatic Spinal Cord Injury Unknown status NCT02326662 Phase 1, Phase 2
16 Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest Unknown status NCT02542306 Phase 2 fibrinogen concentrate
17 Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 Completed NCT02314208 Phase 2 Xenbilox;Tahor
18 Design and Validation of a Modular Physiotherapy Concept for the Treatment of Hereditary Spastic Spinal Paralysis (HSP) - a Randomized Study Completed NCT03961906 Phase 2
19 A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury Completed NCT00500812 Phase 1, Phase 2 Cethrin
20 Multi-center Open Comparative Randomized Trial of Clinical and Neurophysiological Efficacy and Safety of Xeomin (Botulinum Toxin Type A) vs. Botox (Complex of Botulinum Toxin Type A and Hemagglutinin) in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy Completed NCT02188277 Phase 2 Xeomin;Botox®
21 Electrical Stimulation Induced Lower Limb Exercise Capacity, Cardiorespiratory Response, Cardiovascular Risk Factors and Muscle Activity Patterns in Response to Robotic Assisted Treadmill Gait Training in Individuals With Complete Motor Spinal Cord Injury Completed NCT01349478 Phase 1, Phase 2
22 Tri-therapy (SPINALON)-Elicited Spinal Locomotor Network Activation: Phase I-IIa Clinical Trial in Patients With Chronic Spinal Cord Injury Completed NCT01484184 Phase 1, Phase 2 SPINALON (buspirone + levodopa + cardidopa)
23 PCSK9 Inhibitor Treatment for Patients With Hereditary Spastic Paraplegia Type 5 Recruiting NCT04101643 Phase 1, Phase 2 evolocumab
24 Exoskeleton Training After Spinal Cord Injury Recruiting NCT03410550 Phase 2
25 The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Sub-Acute Spinal Cord Injury:A Multicenter, Randomized, Controlled Trial Recruiting NCT03521336 Phase 2 Umbilical Cord Mesenchymal Stem Cells;Placebo
26 The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Early Stage of Chronic Spinal Cord Injury:A Multicenter, Randomized, Controlled Trial Recruiting NCT03521323 Phase 2 Umbilical Cord Mesenchymal Stem Cells;Placebos
27 The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Late Stage of Chronic Spinal Cord Injury:A Multicenter, Prospective, Cohort Study Recruiting NCT03505034 Phase 2 Umbilical Cord Mesenchymal Stem Cells
28 Randomized Clinical Trial for the Evaluation of Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Not yet recruiting NCT02574585 Phase 2
29 A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries Suspended NCT00073853 Phase 2
30 A Prospective, Randomised, Controlled, Open Study. Phase II Treatment Equivalent. Terminated NCT00429013 Phase 2
31 Rehabilitation of the Lower Extremity With AMES Following Incomplete Spinal Cord Injury (SCI) Terminated NCT01498991 Phase 1, Phase 2
32 Intensive Blood PRessure Control in Patients With Acute Type B AortIc Dissection (RAID): Study Protocol for Randomized Controlled Trial Unknown status NCT03001739 Phase 1 Urapidil Hydrochloride Injection
33 Orthostatic Tolerance During FES-evoked Stepping in Paraplegia: A Safety and Viability Study Completed NCT00108043 Phase 1
34 Use of Interactive Gaming After Spinal Cord Injury Completed NCT01537978 Phase 1
35 The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute Spinal Cord Injury (SCI) Completed NCT01739023 Phase 1
36 The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation Completed NCT02354625 Phase 1
37 Improving Ambulatory Community Access After Paralysis Recruiting NCT01570816 Phase 1
38 Tissue Bonding Cystostomy(TBC) Not yet recruiting NCT01771159 Phase 1
39 The ReWalk Exoskeletal Walking System for Persons With Paraplegia Unknown status NCT01454570
40 Computationally Quantifying Wheelchair Set-Up to Minimize Peak Shoulder Joint Forces Throughout Manual Wheelchair Propulsion: A Pilot Study Unknown status NCT00785278
41 Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury Unknown status NCT01386762 Early Phase 1
42 NSC Assistive Technology Research: Reciprocating Gait Orthoses for Paraplegia Patients Unknown status NCT02227407
43 Body Composition Assessment in Spinal Cord Injury Unknown status NCT00957762
44 Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair Unknown status NCT02774096 xenon
45 Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations Unknown status NCT00136630
46 Early Intervention to Reduce Bone Loss After Spinal Cord Injury Unknown status NCT02334410
47 Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias Unknown status NCT00140829
48 Intra-operatory Neurophysiological Monitoring Changes as a Predictive Clinical Outcome Measure in Radiculopathy Associated to Lumbar Disk Disease. Two Years Follow-up Unknown status NCT02185508
49 Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI) Unknown status NCT02559804
50 Abdominal Functional Electrical Stimulation to Augment Breathing in Tetraplegia Unknown status NCT00202631

Search NIH Clinical Center for Paraplegia

Cochrane evidence based reviews: paraplegia

Genetic Tests for Paraplegia

Anatomical Context for Paraplegia

MalaCards organs/tissues related to Paraplegia:

40
Spinal Cord, Bone, Brain, Heart, Prostate, Testes, Thyroid

Publications for Paraplegia

Articles related to Paraplegia:

(show top 50) (show all 12316)
# Title Authors PMID Year
1
Truncating variants in UBAP1 associated with childhood-onset nonsyndromic hereditary spastic paraplegia. 61
31696996 2020
2
Axonal autophagosome maturation defect through failure of ATG9A sorting underpins pathology in AP-4 deficiency syndrome. 61
31142229 2020
3
Open Repair of Proximal Abdominal Aneurysms Analyzed According to the Anatomy, Clamping Site, and Theoretical Fenestrated Endovascular Design. 61
31536799 2020
4
Quality of life, concern of falling and satisfaction of the sit-ski aid in sit-skiers with spinal cord injury: observational study. 61
32034122 2020
5
Traumatic aortic transection repair with distal perfusion - single center experience. 61
31981347 2020
6
Carotid-axillary bypass as an alternative revascularization method for zone II thoracic endovascular aortic repair. 61
32035781 2020
7
Bilateral pure facet joint dislocation in thoracolumbar junction (T11-T12) without facet fracture using a 3D digital printing model for surgical planning: A case report. 61
31872033 2020
8
Spinal cord injury following aortic arch replacement. 61
31332530 2020
9
Resting-State Functional Connectivity of the Thalamus in Complete Spinal Cord Injury. 61
31904298 2020
10
Spinal cord ischemia rescue after hybrid total arch repair with frozen elephant trunk: A case report. 61
32032702 2020
11
Spastic Paraplegia Type 56 in a Young Child. 61
32036589 2020
12
Permanent Paraplegia as a Complication of Injection of Contrast Media at L2-L3 Vertebral Level. 61
31578563 2020
13
Endovascular Therapy for Nonischemic vs Ischemic Complicated Acute Type B Aortic Dissection. 61
31797707 2020
14
Role of Virtual Reality in Balance Training in Patients with Spinal Cord Injury: A Prospective Comparative Pre-Post Study. 61
31575113 2020
15
Spinal cord injury alters purinergic neurotransmission to mesenteric arteries in rats. 61
31774690 2020
16
Congenital Toxoplasmosis Presenting as Eosinophilic Encephalomyelitis With Spinal Cord Hemorrhage. 61
31941759 2020
17
Paraplegia Following Transarterial Chemoembolisation for Hepatocellular Carcinoma: A Case Report. 61
32031042 2020
18
Nontraumatic Myelopathy in Malawi: A Prospective Study in an Area with High HIV Prevalence. 61
31837130 2020
19
Non-motor symptoms are relevant and possibly treatable in hereditary spastic paraplegia type 4 (SPG4). 61
31646384 2020
20
Δ1 -Pyrroline-5-carboxylate synthetase deficiency: An emergent multifaceted urea cycle-related disorder. 61
32017139 2020
21
A cross-sectional comparison between cardiorespiratory fitness, level of lesion and red blood cell distribution width in adults with chronic spinal cord injury. 61
31558360 2020
22
Ophthalmological changes in hereditary spastic paraplegia and other genetic diseases with spastic paraplegia. 61
31865189 2020
23
POLR3A-related spastic ataxia: new mutations and a look into the phenotype. 61
31637490 2020
24
Novel biallelic FA2H mutations in a Japanese boy with fatty acid hydroxylase-associated neurodegeneration. 61
31837835 2020
25
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration. 61
31740269 2020
26
Sorting Rare ALS Genetic Variants by Targeted Re-Sequencing Panel in Italian Patients: OPTN, VCP, and SQSTM1 Variants Account for 3% of Rare Genetic Forms. 61
32028661 2020
27
Poor adherence to influenza vaccination guidelines in spinal cord injury: results from a community-based survey in Switzerland. 61
31371803 2020
28
Bioenergetics and Biomechanics of Handcycling at Submaximal Speeds in Athletes with a Spinal Cord Injury. 61
32013128 2020
29
Traumatic spinal cord injury in Italy 20 years later: current epidemiological trend and early predictors of rehabilitation outcome. 61
31996778 2020
30
Successful treatment of extensive spinal epidural abscess with fluoroscopy-guided percutaneous drainage: a case report. 61
32026104 2020
31
Implantation of Sacral Nerve Stimulator Without Rhizotomy for Neurogenic Bladder in Patient With Spinal Cord Injury: 2-Dimensional Operative Video. 61
31980830 2020
32
The second mutation of SYCE1 gene associated with autosomal recessive nonobstructive azoospermia. 61
31916078 2020
33
Prescription medication cost, insurance coverage, and cost-related nonadherence among people with spinal cord injury in Canada. 61
31900410 2020
34
Effects of a coping-oriented supportive programme for people with spinal cord injury during inpatient rehabilitation: a quasi-experimental study. 61
31253849 2020
35
Satisfaction with access and quality of healthcare services for people with spinal cord injury living in the community. 61
29965779 2020
36
A systematic review and meta-analysis of endovascular versus open surgical repair for the traumatic ruptured thoracic aorta. 61
31327611 2020
37
Three-Dimensional Printing to Guide the Application of Modified Prefenestrated Stent Grafts to Treat Aortic Arch Disease. 61
31917223 2020
38
Advanced weight-bearing mat exercises combined with functional electrical stimulation to improve the ability of wheelchair-dependent people with spinal cord injury to transfer and attain independence in activities of daily living: a randomized controlled trial. 61
31312016 2020
39
Symptomatic Postoperative Spinal Epidural Hematoma after Spinal Decompression Surgery: Prevalence, Risk Factors, and Functional Outcome. 61
31935784 2020
40
Well on wheels intervention: Satisfaction with life and health for adults with spinal cord injuries. 61
30557093 2020
41
Epidural Corticosteroids, Lumbar Spinal Drainage, and Selective Hemodynamic Control for the Prevention of Spinal Cord Ischemia in Thoracoabdominal Endovascular Aortic Repair: A New Clinical Protocol. 61
31721112 2020
42
The Safety and Efficacy of Extended TEVAR in Acute Type B Aortic Dissection. 61
32006479 2020
43
Perceived sleep problems after spinal cord injury: Results from a community-based survey in Switzerland. 61
31977291 2020
44
Two Cases of Very-Late-Onset Neuromyelitis Optica Spectrum Disorder (NMOSD) in Patients over the Age of 80. 61
32009931 2020
45
Cryoablation of Intercostal Nerves Decreased Narcotic Usage After Thoracic or Thoracoabdominal Aortic Aneurysm Repair. 61
31972300 2020
46
Paraspinous muscle gene expression profiling following simulated staged endovascular repair of thoracoabdominal aortic aneurysm: exploring potential therapeutic pathways. 61
31006003 2020
47
Spinal Subarachnoid Hematoma After Cerebrospinal Fluid Drainage in Thoracoabdominal Aortic Aneurysm Repair: Case Report and Literature Review. 61
31605857 2020
48
Assessment of Neurone-Specific Enolase, Glial Fibrillary Acidic Protein and S100 B as Spinal Cord Ischemia Biomarkers in Patients Undergoing Open and Endovascular Complex Aortic Surgery: A Single-Center Experience. 61
31923599 2020
49
Diffuse Midline Glioma H3 K27M-Mutant Manifested as Progressive Paraplegia. 61
31839872 2020
50
Changes in skin-physiology after local heat application using two different methods in individuals with complete paraplegia: a feasibility and safety trial. 61
31911622 2020

Variations for Paraplegia

Copy number variations for Paraplegia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 170541 3 155544315 155572167 Copy number SLC33A1 Paraplegias

Expression for Paraplegia

Search GEO for disease gene expression data for Paraplegia.

Pathways for Paraplegia

Pathways related to Paraplegia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.42 ZFYVE27 WASHC5 SPG21 SPART KIF5A

GO Terms for Paraplegia

Cellular components related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.91 ZFYVE27 WASHC5 SPAST SLC33A1 RTN2 REEP1
2 endoplasmic reticulum membrane GO:0005789 9.76 ZFYVE27 SPAST SLC33A1 RTN2 REEP1 ERLIN2
3 axon GO:0030424 9.62 ZFYVE27 SPG11 KIF1A ATL1
4 endoplasmic reticulum tubular network GO:0071782 9.13 ZFYVE27 REEP1 ATL1
5 axon cytoplasm GO:1904115 8.92 SPG7 SPAST KIF5A KIF1A

Biological processes related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synaptic vesicle transport GO:0048489 9.16 SPG11 KIF5A
2 retrograde neuronal dense core vesicle transport GO:1990049 8.96 KIF5A KIF1A
3 anterograde axonal transport GO:0008089 8.8 SPG7 SPAST KIF1A

Molecular functions related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.09 ZFYVE27 ZFYVE26 WASHC5 SPG7 SPG21 SPG11
2 microtubule binding GO:0008017 9.26 SPAST REEP1 KIF5A KIF1A
3 ATPase activity GO:0016887 8.92 SPAST KIF5A KIF1A HSPD1

Sources for Paraplegia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....